Free Trial

Adaptimmune Therapeutics (ADAP) SEC Filings & 10K Form

Adaptimmune Therapeutics logo
$0.67 +0.01 (+0.80%)
(As of 09:00 AM ET)

Recent Adaptimmune Therapeutics SEC Filings

DateFilerForm TypeView
11/13/2024
8:04 AM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SC 13G/A
11/13/2024
8:10 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
4:00 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/23/2024
3:15 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
6:23 AM
Adaptimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2024
6:05 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/02/2024
6:00 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2024
3:30 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2024
6:39 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2024
6:14 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2024
6:34 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/22/2024
4:15 PM
Adaptimmune Therapeutics (Filer)
Form ARS
04/12/2024
7:05 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/11/2024
7:00 AM
Adaptimmune Therapeutics (Filer)
Form DEF 14A
04/02/2024
7:38 PM
Adaptimmune Therapeutics (Subject)
New Enterprise Associates 14, L.P. (Filed by)
Form SC 13D/A
04/01/2024
7:01 AM
Adaptimmune Therapeutics (Filer)
Form PRE 14A
03/26/2024
10:59 AM
Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
Form SC 13G/A
03/26/2024
11:00 AM
Adaptimmune Therapeutics (Issuer)
EcoR1 Capital, LLC (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2024
6:05 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
6:12 AM
Adaptimmune Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2024
7:13 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/31/2024
4:07 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/30/2024
4:26 PM
Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
Form SC 13G
01/29/2024
10:52 AM
Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
Form SC 13G/A
01/17/2024
4:30 PM
Adaptimmune Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:30 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:30 PM
Adaptimmune Therapeutics (Issuer)
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:31 PM
Adaptimmune Therapeutics (Issuer)
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:31 PM
Adaptimmune Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:31 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:00 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:01 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:01 PM
Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:01 PM
Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:02 PM
Adaptimmune Therapeutics (Issuer)
Brewer Joanna Elizabeth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:02 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:03 PM
Adaptimmune Therapeutics (Issuer)
Hege Kristen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:03 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
4:06 PM
Adaptimmune Therapeutics (Issuer)
Behbahani Ali (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
6:46 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/06/2023
6:13 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address. 
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ADAP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners